Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 3, 2011, Pages 417-420

  Feasey, Nick A ^a,b,c   Pond, M ^b,d   Coleman, D ^b   Solomon, A W ^c,e   Cosgrove, C A ^b,c   Delgado, R ^c   Butcher, P D ^b   Mitchison, D A ^b   Harrison, T ^b,c  

^a MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Fluoroquinolones; Multidrug resistant; Pyrazinamide; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE; STREPTOMYCIN;

ADD ON THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BONE MARROW SUPPRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; HUMAN; LUNG CAVITATION; LUNG NODULE; MALE; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SPUTUM SMEAR; TINNITUS; TREATMENT RESPONSE;

ADULT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PYRAZINAMIDE; QUINOLINES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79951666304     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. WHO/HTM/TB/2004.343. Geneva, Switzerland; WHO, 2004.
2. Specific laboratory tests in streptomycin therapy of tuberculosis. Lancet 1948; 2: 862-865.
3. Laboratory techniques for the determination of sensitivity of tubercle bacilli to isoniazid, streptomycin, and PAS. Lancet 1953; 265: 213-217.
4. Gumbo T, Louie A, Deziel M R, Parsons L M, Salfinger M, Drusano G L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
5. Gumbo T. New susceptibility breakpoints for first-line antit uberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484-1491.
6. Marks J. A system for the examination of tubercle bacilli and other mycobacteria. Tubercle 1976; 57: 207-225.
7. Collins C H, Grange J M, Yates J M. Organization and practice in tuberculosis bacteriology. 2nd ed. London, UK: Butterworths, 1997.
8. Welch D F, Guruswamy A P, Sides S J, Shaw C H, Gilchrist M J. Timely culture for mycobacteria which utilizes a microcolony method. J Clin Microbiol 1993; 31: 2178-2184. (Pubitemid 23210515)
9. Mitchison D A, Allen B W, Carrol L, Dickinson J M, Aber V R. A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol 1972; 5: 165-175.
10. Brander E. A simple way of detecting pyrazinamide resistance. Tubercle 1972; 53: 128-131.
11. Tobin C M, Sunderland J, White L O, MacGowan A P, Reeves D S. An isocratic high performance liquid chromatography (HPLC) assay for moxifloxacin, a new 8-methoxyquinolone. J Antimicrob Chemother 1998; 42: 278-279. (Pubitemid 28393608)
12. Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
13. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-543.
14. Sandgren A, Strong M, Muthukrishnan P, Weiner K, Church G M, Murray M B. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
15. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher L M. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-112.